Traduction de «for otc development and commercialization » (Néerlandais → Français) :

Novartis gained the rights for OTC development and commercialization of Prevacid ® from Takeda Pharmaceuticals North America, Inc.
Novartis a obtenu les droits de développer et de commercialiser Prevacid ® dans une version OTC de Takeda Pharmaceuticals North America, Inc.

Growth New products, the result of successful R&D investments, are rejuvenating the Novartis portfolio together with initiatives to strengthen positions in emerging markets, build global businesses of scale, develop new commercial skills and improve talent.
Croissance Les nouveaux produits, dus à des investissements en R&D couronnés de succès, renouvellent le portefeuille de Novartis. En même temps, le Groupe lance des projets visant à renforcer les positions dans les marchés émergents, déployer des activités d’envergure mondiale afin de réaliser des économies d’échelle, développer de nouveaux savoir-faire commerciaux et améliorer les talents.

Pharmaceuticals – Corthera On February 3, Novartis completed the acquisition of the privately held US based Corthera Inc., gaining worldwide rights to Relaxin for the treatment of acute decompensated heart failure and assumed full responsibility for development and commercialization for a total purchase consideration of USD 327 million.
Pharmaceuticals – Corthera Le 3 février, Novartis a achevé l’acquisition de Corthera Inc., une entreprise américaine non cotée, pour un prix total d’USD 327 millions.

Novartis will assume full responsibility for development and commercialization.
Novartis assumera la responsabilité pleine et entière du développement et de la commercialisation de ce médicament.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

In October, Novartis signed a collaboration agreement with Cepheid for the commercialization and further development of a test for monitoring of bcr-abl gene transcript.
En octobre, Novartis a signé un accord de collaboration avec Cepheid pour la commercialisation et la poursuite du développement d’un test de surveillance du gène transcrit bcr-abl.